Morning Briefing
Summaries of health policy coverage from major news organizations
New Migraine Drug Will 'Change The Paradigm' Of Treatment, Says CEO
Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company鈥檚 migraine drug will 鈥渃hange the paradigm鈥 of migraine prevention and treatment. The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric. (Clifford, 6/8)
Louisiana hospitals are cheering a new state law that bans health insurers' controversial practice of white bagging, or bypassing hospital pharmacies for certain drugs. Across the country, health insurers are increasingly setting policies that funnel services away from hospitals in favor of less expensive settings. In this case, they're shipping doses of expensive physician-administered drugs, commonly cancer infusions, directly to hospitals instead of allowing hospitals to buy them using discounts and retrieve them from their in-house pharmacies. Insurers have defended the practice by arguing that getting drugs from their own network of specialty pharmacies helps keep healthcare more affordable. (Bannow, 6/8)
Two prominent shareholder advisory firms are urging Regeneron Pharmaceuticals (REGN) shareholders to remove a director who is on the compensation committee, citing concerns over 鈥減roblematic鈥 pay practices and 鈥渆xcessive鈥 awards given to the top two executives. In separate investor alerts, the advisory firms argue the Regeneron board has showered chief executive officer Leonard Schleifer and president and chief scientific officer George Yancopoulos with upfront performance stock units worth $130 million over five years, rather than annual grants. This approach may lock in executives, but the firms say it also robs the board of flexibility if job performance changes during that time. (Silverman, 6/8)
The US Food and Drug Administration (FDA) has approved Tembexa (brincidofovir) to treat smallpox. This is the second approved smallpox drug; the first, TPOXX (tecovirimat), was approved in 2018.The World Health Organization declared smallpox eradicated in 1980, but since then many nations have expressed concerns that the variola virus, which causes smallpox, could be used as a bioweapon. (6/8)
In updates on the opioid crisis 鈥
While a retired high-ranking official with the Drug Enforcement Administration said drug distributors鈥 neglect in reporting suspicious opioid pill orders was part of a systemic failure, the defendants said the real issue was with the regulator鈥檚 practices. The official 鈥 Joe Rannazzisi, head of the Office of Diversion Control for the DEA from 2006 to 2015 鈥 testified Tuesday in Charleston at the ongoing opioid trial. Cabell County and Huntington are accusing the 鈥淏ig Three鈥 drug wholesalers 鈥 AmerisourceBergen, Cardinal Health and McKesson 鈥 of fueling the opioid crisis by sending excessive shipments of opioids into the area for eight years before a reduction in the number of pills shipped made users turn to illicit drugs. (Hessler, 6/8)
San Francisco police arrested five men and seized 16 pounds of fentanyl 鈥 enough to kill the city鈥檚 population four times over 鈥 in a narcotics operation in Oakland meant to block deadly drugs from entering the city鈥檚 Tenderloin neighborhood, authorities said Tuesday. The arrests and seizures last Thursday involved two semi-automatic guns that were not registered, more than $45,000 in cash and nearly 30 pounds of drugs, including the fentanyl. (Hern谩ndez, 6/8)